Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone412-586-5830
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees37
Next Earnings Date8/5/2019 (Estimated)
OptionableNot Optionable
Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions
What is Krystal Biotech's stock symbol?
Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How were Krystal Biotech's earnings last quarter?
Krystal Biotech Inc (NASDAQ:KRYS) posted its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. View Krystal Biotech's Earnings History.
When is Krystal Biotech's next earnings date?
What price target have analysts set for KRYS?
6 equities research analysts have issued twelve-month price objectives for Krystal Biotech's stock. Their forecasts range from $34.00 to $57.50. On average, they expect Krystal Biotech's share price to reach $41.8750 in the next year. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Price Targets for Krystal Biotech.
What is the consensus analysts' recommendation for Krystal Biotech?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech.
What are Wall Street analysts saying about Krystal Biotech stock?
Here are some recent quotes from research analysts about Krystal Biotech stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our target to $38 from $32. The changes to our valuation include: (1) adjustment to base year to reflect the current NPV relative to our September 2018 initiation of coverage; and (2) increasing our projected chance of success for to 15%. We are currently leaving our projected chance of success for KB103 the same, at 25%, and await the pending clinical update this quarter." (5/24/2019)
- 2. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (5/9/2019)
- 3. William Blair analysts commented, "We continue to view the anticipated second quarter clinical update of the GEM trial as a significant near-term catalyst for shares. As we have noted previously (see our note, We See Durable Wound Closure and 30%-40% COL7A1 Expression as after reviewing the published literature, we believe that achieving roughly 30%-40% of wild-type (normal) levels of collagen VII could be sufficient to restore skin integrity and prevent skin blistering. We also believe that the presence of anchoring fibrils should be viewed qualitatively only due to its lack of direct correlation with clinical results." (5/6/2019)
- 4. Chardan Capital analysts commented, "We consider PRIME Designation (and RMAT/BTD) as a leading indicator for outperformance in the gene therapy space. Krystal announced today the European Medicines Agency (EMA) has granted access to its PRIME scheme for KB103 (bercolagene telserpavec), a 1st-in-class topical gene therapy (GT) for DEB. Krystal’s application and the designation were supported by data so far from the ongoing GEM-1 phase I/II study and non-clinical data. Recall that for a medicine to be accepted for PRIME, it has to show the potential to meet unmet medical needs based on early clinical data, plus preclinical data. With PRIME access, KB103 is now eligible for enhanced dialogue with the European regulator, and a pathway for accelerated approval. PRIME access to us is consistent with Krystal’s plans for KB103 filings by 2020E." (3/29/2019)
Has Krystal Biotech been receiving favorable news coverage?
Headlines about KRYS stock have trended positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Krystal Biotech's key competitors?
Some companies that are related to Krystal Biotech include Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Alector (ALEC), Fate Therapeutics (FATE), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), GENFIT S A/ADR (GNFT) and Voyager Therapeutics (VYGR).
What other stocks do shareholders of Krystal Biotech own?
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the folowing people:
- Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)
- Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)
- Ms. Pooja Agarwal, VP of Product Devel. (Age 40)
- Mr. Antony A. Riley, Chief Financial Officer (Age 51)
- Ms. Gloria Lin, Accounting Mang.
When did Krystal Biotech IPO?
(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.
Who are Krystal Biotech's major shareholders?
Krystal Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (2.25%), S Squared Technology LLC (0.48%), Blair William & Co. IL (0.46%), BlackRock Inc. (0.38%), Laurion Capital Management LP (0.26%) and P.A.W. Capital Corp (0.24%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.
Which institutional investors are selling Krystal Biotech stock?
KRYS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, P.A.W. Capital Corp, S Squared Technology LLC, Morgan Stanley, New York State Common Retirement Fund, Acadian Asset Management LLC, Redmile Group LLC and Northern Trust Corp. View Insider Buying and Selling for Krystal Biotech.
Which institutional investors are buying Krystal Biotech stock?
KRYS stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, BlackRock Inc., Laurion Capital Management LP, Tibra Equities Europe Ltd, ExodusPoint Capital Management LP, Citigroup Inc., Neuberger Berman Group LLC and BlueCrest Capital Management Ltd. Company insiders that have bought Krystal Biotech stock in the last two years include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech.
How do I buy shares of Krystal Biotech?
Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Krystal Biotech's stock price today?
One share of KRYS stock can currently be purchased for approximately $32.44.
How big of a company is Krystal Biotech?
Krystal Biotech has a market capitalization of $468.56 million. The company earns $-10,890,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.
What is Krystal Biotech's official website?
How can I contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.
MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
